Loading
A phase 3 trial of Nivolumab, Pembrolizumab, Carboplatin in non-small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% is a phase 3 interventional study registered as NCT06561386 by Bristol-Myers Squibb, with 1000 participants planned, started 2024-10-07 and due to reach its primary completion in 2030-07-30. Interventions recorded: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares T-cell exhaustion and CAR-T persistence, Pemetrexed, Small-cell lung cancer, Cisplatin.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Small-cell lung cancer, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Small-cell lung cancer, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/